<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
h1
{mso-style-priority:9;
mso-style-link:"Heading 1 Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:24.0pt;
font-family:"Times New Roman","serif";
font-weight:bold;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
span.Heading1Char
{mso-style-name:"Heading 1 Char";
mso-style-priority:9;
mso-style-link:"Heading 1";
font-family:"Cambria","serif";
color:#365F91;
font-weight:bold;}
span.date
{mso-style-name:date;}
span.EmailStyle21
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>See below for an article with Canadian basis.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Dr. Loblaw also discussed this during a PCC “Expert Angle” webinar in November 2014.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Go to the PCC web site to look it up.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>May be a topic to have the October speaker discuss.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Take care,<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Glen <o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Chair PCCN W-W<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>Sent:</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'> October 14, 2015 11:17 AM<br><br><b>Subject:</b> FYI From ctvnews.ca Topic: Toronto hospital tests new, high-precision method<o:p></o:p></span></p></div><p class=MsoNormal><o:p> </o:p></p><div><h1><span style='font-size:13.5pt'>Toronto hospital tests new, high-precision method of prostate cancer treatment </span><o:p></o:p></h1><p>CTV Toronto <br><span class=date>Published Monday, October 12, 2015 9:47PM EDT </span><o:p></o:p></p><div><p>Doctors at Toronto’s Sunnybrook Hospital are exploring a new, more precise way of administering radiation therapy to patients with prostate cancer.<o:p></o:p></p><p><o:p> </o:p></p><p>Stereotactic ablative body radiotherapy, or SABR, allows doctors to give patients a high dose of radiation in a short period of time, replacing the long hours of treatment commonly associated with radiation therapy.<o:p></o:p></p><p><o:p> </o:p></p><p>“What’s really revolutionary about this is that patients used to have to come for up to eight weeks of radiotherapy -- one treatment per day, five days a week,” said Sunnybrook oncologist Andrew Loblaw. “Now with this new trial, we’ve been able to show that you can do that as few as five times.”<o:p></o:p></p><p><o:p> </o:p></p><p>SABR trials began in 2006 on low-risk cancer patients. Results were so successful that moderate-risk and even high-risk patients are now included in the testing.<o:p></o:p></p><p><o:p> </o:p></p><p>“The preliminary to date show that the impact, in terms of side-effects, are no worse than the standard course of treatment,” said Wiliam Chu, one of the doctors behind the trial.<o:p></o:p></p><p>Survival rates after the treatment are comparable and, in some cases, even better than regular radiotherapy.<o:p></o:p></p><p>And the cost of the five SABR sessions is less than a quarter of the cost of 39 weeks of standard treatment.<o:p></o:p></p><p><o:p> </o:p></p><p>Loblaw says the new treatment also benefits patients’ lifestyles.<o:p></o:p></p><p>“It’s very easy to put a 15-minute treatment into your work schedule or your life schedule compared to coming in for 15 to 30 minutes every single day,” he said.<o:p></o:p></p><p><o:p> </o:p></p><p>Brad Brown, was offered several therapy option when he was diagnosed with prostate cancer, but opted for SABR.<o:p></o:p></p><p>“The other (treatments) weren’t terrible attractive,” he said. “Surgery had a long recovery time, some of them were quite expensive, others took a big time commitment.”<o:p></o:p></p><p>Brown has not suffered any negative side-effects while receiving the SABR treatment.<o:p></o:p></p><p><o:p> </o:p></p><p>Trials of the SABRE technology are being expanded to several cancer centres across Canada, including Montreal, Calgary, Sudbury, and Winnipeg.<o:p></o:p></p><p>Sunnybrook is the only hospital doing trials with high-risk cancer patients.<o:p></o:p></p><p><o:p> </o:p></p><p><em>With a report from Pauline Chan </em><o:p></o:p></p><p><o:p> </o:p></p><p><o:p> </o:p></p><p><o:p> </o:p></p><p><em><a href="url:http://toronto.ctvnews.ca/toronto-hospital-tests-new-high-precision-method-of-prostate-cancer-treatment-1.2606790"><span style='font-style:normal'>url:http://toronto.ctvnews.ca/toronto-hospital-tests-new-high-precision-method-of-prostate-cancer-treatment-1.2606790</span></a></em><o:p></o:p></p></div></div><p class=MsoNormal>-- <br>You received this message because you are subscribed to the Google Groups "FYI Prostate Info" group.<br>To unsubscribe from this group and stop receiving emails from it, send an email to <a href="mailto:fyi-prostate-info+unsubscribe@googlegroups.com">fyi-prostate-info+unsubscribe@googlegroups.com</a>.<br>To post to this group, send email to <a href="mailto:fyi-prostate-info@googlegroups.com">fyi-prostate-info@googlegroups.com</a>.<br>To view this discussion on the web visit <a href="https://groups.google.com/d/msgid/fyi-prostate-info/db75eaee-8fdc-4067-9e39-8747ecf2091c%40googlegroups.com?utm_medium=email&utm_source=footer">https://groups.google.com/d/msgid/fyi-prostate-info/db75eaee-8fdc-4067-9e39-8747ecf2091c%40googlegroups.com</a>.<br>For more options, visit <a href="https://groups.google.com/d/optout">https://groups.google.com/d/optout</a>.<o:p></o:p></p></div></body></html>